Choroidal neovascularisation secondary to Best's disease in a 13-year-old boy treated by intravitreal bevacizumab.
BACKGROUND
To describe the effect of intravitreal bevacizumab for the treatment of choroidal neovascularisation secondary to vitelliform dystrophy of the macula (Best's disease).


METHODS
A 13-year-old boy with confirmed Best's disease presented with visual acuity (VA) loss due to secondary choroidal neovascularisation (CNV). He was treated with a single injection of 1-mg bevacizumab.


RESULTS
Best corrected VA (Snellen) fully recovered from 20/40 preoperatively to 20/20 over a period of 6 months. Optical coherence tomography (OCT) and angiography demonstrated regression of the CNV and resolution of the macular edema.


CONCLUSIONS
A single intravitreal injection of bevacizumab may be effective to induce morphologic and functional improvement in a juvenile suffering from CNV secondary to Best's disease.
Leu
Jörg
J
Department of Ophthalmology, Cologne Hospitals, Cologne, Germany.
Schrage
Norbert F
NF
Degenring
Robert F
RF
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D012162:Retinal Degeneration / Q000150:complications / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab